drugset / Trial / NCT00002234
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
Phase 2
Completed
25 enrolled
Gilead Sciences
Bristol-Myers Squibb · collabDupont Applied Biosciences · collabGlaxo Wellcome · collab
Treatment
Summary
The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adefovir dipivoxil | Small molecule | — | — |
| Subject | Didanosine | Small molecule | — | — |
| Subject | Efavirenz | Other / unclassified | — | — |
| Subject | Lamivudine | Other / unclassified | — | — |